Allergan Inc. Comments on Order Regarding Permanent Injunction Against Merz Pharmaceuticals, LLC and Merz Aesthetics (Formerly Known as BioForm Medical, Inc.)
Published: Oct 02, 2012
IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc. (NYSE:AGN) confirms that U.S. District Judge Andrew J. Guilford has entered an order providing that the injunction against Merz Aesthetics prohibiting it from, among other things, selling or soliciting purchases of its product Xeomin® in the facial aesthetics market, shall remain in place until January 9, 2013. The order also provides that the terms of the injunction that restrict Merz Aesthetics’ ability to sell and solicit purchases of its dermal fillers, as well as the terms that restrict Merz Pharmaceuticals’ ability to sell and solicit purchases of Xeomin® in the therapeutic market, shall remain in place until November 1, 2012. The order follows the court’s ruling in March 2012 issuing a permanent injunction against Merz, concluding the company misappropriated important trade secrets belonging to Allergan regarding its products BOTOX® Cosmetic (onabotulinumtoxinA), BOTOX® (onabotulinumtoxinA) and JUVÉDERM®.